Neurocrine Biosciences Inc
NASDAQ:NBIX
Neurocrine Biosciences Inc
Cash from Operating Activities
Neurocrine Biosciences Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
Cash from Operating Activities
$389.9m
|
CAGR 3-Years
19%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
See Also
What is Neurocrine Biosciences Inc's Cash from Operating Activities?
Cash from Operating Activities
389.9m
USD
Based on the financial report for Dec 31, 2023, Neurocrine Biosciences Inc's Cash from Operating Activities amounts to 389.9m USD.
What is Neurocrine Biosciences Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
31%
Over the last year, the Cash from Operating Activities growth was 15%. The average annual Cash from Operating Activities growth rates for Neurocrine Biosciences Inc have been 19% over the past three years , 31% over the past five years .